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ARTICLE
A Homozygous Mutation in a Novel Zinc-Finger Protein, ERIS,
Is Responsible for Wolfram Syndrome 2
Sami Amr, Cindy Heisey, Min Zhang, Xia-Juan Xia, Kathryn H. Shows, Kamel Ajlouni, Arti Pandya,
Leslie S. Satin, Hatem El-Shanti, and Rita Shiang
A single missense mutation was identified in a novel, highly conserved zinc-finger gene, ZCD2, in three consanguineous
families of Jordanian descent with Wolfram syndrome (WFS). It had been shown that these families did not have mutations
in the WFS1 gene (WFS1) but were mapped to the WFS2 locus at 4q22-25. A GrC transversion at nucleotide 109 predicts
an amino acid change from glutamic acid to glutamine (E37Q). Although the amino acid is conserved and the mutation
is nonsynonymous, the pathogenesis for the disorder is because the mutation also causes aberrant splicing. The mutation
was found to disrupt messenger RNA splicing by eliminating exon 2, and it results in the introduction of a premature
stop codon. Mutations in WFS1 have also been found to cause low-frequency nonsyndromic hearing loss, progressive
hearing loss, and isolated optic atrophy associated with hearing loss. Screening of 377 probands with hearing loss did
not identify mutations in the WFS2 gene. The WFS1-encoded protein, Wolframin, is known to localize to the endoplasmic
reticulum and plays a role in calcium homeostasis. The ZCD2-encoded protein, ERIS (endoplasmic reticulum intermem-
brane small protein), is also shown to localize to the endoplasmic reticulum but does not interact directly with Wolframin.
Lymphoblastoid cells from affected individuals show a significantly greater rise in intracellular calcium when stimulated
with thapsigargin, compared with controls, although no difference was observed in resting concentrations of intracellular
calcium.
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Wolfram syndrome (WFS [MIM 222300]) is an autosomal
recessive disorder with severe neurodegeneration. Affected
individuals present with juvenile-onset insulin-dependent
diabetes mellitus and optic atrophy.1,2 Other neurological
and endocrine manifestations include diabetes insipidus,
sensorineural deafness, dementia, psychiatric illnesses,
renal-tract abnormalities, and bladder atony.3,4 One gene
for the disorder, WFS1, on chromosome 4p16.3, has been
cloned and encodes a novel transmembrane protein lo-
cated in the endoplasmic reticulum (ER) and may play a
role in calcium (Ca2) homeostasis.5–8 In addition, domi-
nant mutations in the WFS1 gene have been shown to
play a role in low-frequency sensorineural hearing loss, pro-
gressive hearing loss, and deafness with optic atrophy.9–11
The locus for WFS2 (MIM 604928) was mapped to chro-
mosome 4q22-24 between markers D4S1591 and D4S3240
in three large, consanguineous Jordanian families.12 Al-
though the families are not related, haplotype analysis
shows a common affected haplotype among the families.
An extensive phenotypic analysis showed additional
symptoms in individuals with WFS2, such as significant
bleeding tendency, as well as a defective platelet aggre-
gation with collagen,13 which has not been previously de-
scribed in families with WFS. In addition, a considerable
number of the patients had peptic ulcer disease that was
compounded by the bleeding tendency, causing gastro-
intestinal-tract bleeding.14
In this study, we identified a mutation causative for
WFS2 in a novel, highly conserved zinc-finger gene, ZCD2,
that is located within the critical gene region. In addition,
evidence of the pathogenetic nature of the mutation was
revealed. Additional studies of this novel gene include the
characterization of its protein domains, expression, and
cellular localization and studies to determine whether
there is a role for this gene in Ca2 homeostasis. To de-
termine whether the WFS2 gene is also associated with
nonsyndromic hearing loss, mutation analysis with a




New genetic markers in the 4q24-q25 region were identified by
searching for microsatellite regions in genomic DNA with use of
the program Sputnik. Four new microsatellite clusters were iden-
tified within the critical gene region. Primers to amplify the re-
gion were developed and were tested in 10 unrelated CEPH in-
dividuals (all primers here and below are shown 5′r3′) (Wpoly2F
[tgactagttgatgggtgcag], Wpoly2R [ccaaacgctagtgagatgtg], Wpoly5F
[caatatcccatactgagagtc], Wpoly5R [tgcatgttctgaacacgtac], Wpoly6F
[actgttggtagatgtcagtc], Wpoly6R [gaccacatcttctgtgtgcc], Wpoly7F
[atgctgtacgttctagccag], and Wpoly7R [gtgatcttgtattctgcaacc]). All
microsatellites were found to be polymorphic, with heterozygos-
ities of 0.79 for Wpoly2, 0.81 for Wpoly5, 0.78 for Wpoly6, and
0.82 for Wpoly7. These markers and other known markers in the
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region (D4S2961, D4S3043, D4S1572, D4S2913, D4S411,
D4S1531, and D4S2917) were typed in the WFS2-affected families.
Primers were end labeled with g-P33, and annealing temperatures
were 60C for Wpoly2, Wpoly5, and Wpoly6 and 65C for
Wpoly7. Samples were run on sequencing gels and were exposed
to x-ray film.
SSCP Analysis
Primer sets were individually optimized for single-band amplifi-
cation. Samples were prepared by mixing 7 ml of PCR products
with 3 ml SSCP loading dye (95% formamide, 20 mM EDTA, 0.05%
xylene cyanol, and 0.05% bromophenol blue), were denatured at
95C for 5 min, and were quickly cooled on ice. Three samples
were run for each primer set: the patient PCR product, the control
PCR product, and the patient plus control PCR products. Dena-
tured samples were run through a 10% (49:1) acrylamide:bis-
acrylamide gel (National Diagnostics) with 1# Tris-borate EDTA
(TBE) and 10% glycerol either at 8 W for 5 h at 4C or at 3 W
for 16 h at 4C after a 30-min prerun. Gels were stained in SYBR
Gold (Molecular Probes) diluted 1:10,000 in 1# TBE, in accor-
dance with the manufacturer’s protocol.
ZCD2 PCR and Restriction-Enzyme Digest
Four sets of primers were synthesized to amplify exons 1–3 of the
ZCD2 gene from genomic DNA: Exon1F (gctcgggagaggagttgac)
and Exon1R (ggatttttacgcctccttcc), Exon2aF (agcactgcagattctgac-
aca) and Exon2aR (cgttttagaacgccaacacc), Exon2bF (tcgcacttcttgg-
ctacctt) and Exon2bR (ggggatttaagaggcgaaac), and Exon3F (gctttc-
tttctgagagcatttc) and Exon3R (ccagtagtaataattaagaccaccatt). PCR
was performed using an annealing temperature of 65C. The mu-
tation was screened by digesting the 249-bp Exon2a PCR product
with XmnI by use of the manufacturer’s conditions (NEB). ZCD2
exon 2 from an affected individual from each family was se-
quenced, to confirm the change. The use of these samples was
approved by the Virginia Commonwealth University and Jordan
University of Science and Technology institutional review boards
(IRBs), and informed consent or assent, when appropriate, was
obtained from all subjects.
TaqMan Genotyping
To calculate the allele frequency of the mutation, a Custom
TaqMan SNP Genotyping Assay (Applied Biosystems) was de-
signed specific to the detection of this single base change. This
methodology uses 5′ fluorogenic chemistry and TaqMan probes.
An ABI PRISM 7900 sequence detection system was used for ge-
notyping the control cohorts. An affected individual (W2) from
family WS-2 and two obligate carriers were used as homozygous
and heterozygous controls, respectively, after the genotype was
confirmed by sequencing. The genotype was confirmed by se-
quencing in 88 randomly chosen DNA samples (20%) of the sam-
ples from 440 Jordanian controls.
Control Cohorts
The three control cohorts include an ethnically matched cohort
of 440 unrelated Jordanian controls. In addition, 1,064 controls
obtained from the Human Genome Diversity Project (HGDP)–
CEPH Human Genome Diversity Cell Line Panel15 and 86 unre-
lated CEPH controls were used. The HGDP-CEPH panel contains
148 individuals of the same ethnic background as the three fam-
ilies. These cohorts represent a total of 3,180 chromosomes, of
which 1,176 are ethnically matched.
Hearing-Loss Cohorts
Of the 377 probands with hearing loss who were screened, 288
were from multiplex families indicating a recessive mode of in-
heritance and had severe-to-profound hearing loss. We also
screened 84 probands with moderate-to-severe autosomal dom-
inant hearing loss. The probands were classified as autosomal
dominant if there is a family history of hearing loss with vertical
transmission and if the hearing loss is postlingual and progressive.
Although the majority had severe-to-profound hearing loss, 14
individuals had high-frequency hearing loss, but only 1 individ-
ual had low-frequency hearing loss. The use of these samples was
approved by the Virginia Commonwealth University IRB, and
informed consent or assent, when appropriate, was obtained from
all subjects.
Cell Culture
Two control (W1 and JA) and one affected (W2) lymphoblastoid
cell lines from the Jordanian population were maintained in RPMI
1640 with L-glutamate (Invitrogen) supplemented with 10% fetal
bovine serum (FBS). P19 mouse embryonic carcinoma cells were
grown in a–minimum essential medium (Invitrogen) supple-
mented with 7.5% bovine calf serum, 2.5% FBS, and 0.5% gen-
tamicin. HEK293 human embryonic kidney cells were maintained
in Dulbecco’s modified Eagle’s medium (Invitrogen) supple-
mented with 10% FBS and 1% penicillin and streptomycin. All
cell lines were maintained in a 5% CO2 incubator that was kept
at 37C. P19 and HEK293 cells that were going to be transfected
were maintained in the described media without antibiotic
supplementation.
Protein Analysis
The protein sequence was analyzed through Prosite16 and
PhosphoMotif Finder of the Human Protein Reference Database
to identify putative protein motifs.17 To identify homologues of
the gene, the protein was searched through use of the basic local
alignment search tool nucleotide database (BLAST: tBLASTn).18
RT-PCR
Total RNA was extracted from W1, W2, and JA human lympho-
blastoid cells by use of Trizol (Invitrogen). Total RNA was treated
with 20 U of RQ1 DNase (Promega). First-strand cDNAs were gen-
erated from 500 ng of total RNA with 5 ng/ml of both oligo dT
and random primers and 0.5 mM deoxynucleotide triphosphates
(dNTPs), then they were heated to 65C for 5 min and were cooled
immediately afterwards on ice. First-strand buffer (1#), 0.01 M
dithiothreitol, and 40 U RNase inhibitor (Promega) were then
added, and the mixture was incubated at 37C for 2 min. An
aliquot of 200 U of Moloney murine leukemia virus–reverse tran-
scriptase (Invitrogen) was added, and the reaction was allowed
to take place at 37C for 50 min, followed by a final incubation
at 70C for 15 min.
Transcript-specific primers used for amplification of ZCD2
cDNA were pogo.aRTF (gctcgggagaggagtgga) and pogo.aRTR(tgca-
ggaagaaaataaattggaa). GADPH primers used were GADPHF (acttc-
aacagcgacacccactc) and GADPHR (ccctgttgctgtagccaaattc). PCR
was performed in 12.5-ml reactions containing 1.25 ml of cDNA,
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1# PCR buffer (GeneChoice), 0.2 mM dNTPs, 0.26 pmol/ml of
each primer, and 0.25 U of Taq polymerase (GeneChoice). The
primers were annealed at 63C.
Expression-Vector Construct and Transfection
Two mammalian expression vectors containing a FLAG-tagged
ZCD2 cDNA were constructed, one of which had the FLAG on
the N-terminus, and the other on the C-terminus. The FLAG tags
with restriction-enzyme ends were generated using oligonucle-
otides and were inserted into the destination vector pDEST26
(Invitrogen). For the N-terminus FLAG tag, the primers were ggac-
catggcgtactacgactacaaagacgatgacgacaagt and gcggaccatggcgtacta-
cgactacaaagacgatgacgacaagtctag, which create a SacII site at the
5′ end and an XbaI site at the 3′ end. For the C-terminus FLAG
tag, the primers were gtacaaagtggttgactacaaagacgatgacgacaagtgag-
acgt and aaagtggttgactacaaagacgatgacgacaagtgag, which create a
BsrGI site at the 5′ end, then an attB2 site upstream of the FLAG
sequence, followed by a stop codon, and an AatII site at the 3′
end.
For the N-terminus FLAG construct, the FLAG-tag sequence was
cloned into pDEST26 by use of SacII and XbaI sites. For the C-
terminus FLAG-tag construct, a fragment from pDEST26 was ex-
cised using SalI and HindIII and was cloned into pBluescript KS
(Stratagene); then, the C-terminus FLAG tag was cloned into the
pDEST26 fragment by use of the BsrGI and AatII sites; and, finally,
the pDEST26 fragment containing the FLAG tag was cloned back
into the SalI and NheI sites of the pDEST26 vector.
ZCD2 cDNA was obtained from IMAGE clone 5105935 (Invi-
trogen). It was subcloned into the EcoRI and XhoI sites of the
entry vector pENTR3C (Invitrogen), creating pENTR5105935. To
create the fusion protein with the FLAG tag at the C-terminus, a
ZCD2 cDNA without a stop codon was generated by PCR using
the primers pENTR3C-F2 (tggcttttttgcgtttctac) and pogo3′no stop
XhoR (gccgctcgaggctacttctttcttcttcagtattagtg), with use of
pENTR5105935 as a template, and was cloned into the EcoRV
site of pBluescript SK (Stratagene). The integrity of the clone
was checked by sequencing, and then it was subcloned into the
vector pENTR3C by use of EcoRI/XhoI sites.
The ZCD2 cDNA and the ZCD2 no-stop cDNA in the pENTR3C
vectors were cloned into the N-terminus FLAG-tag pDEST26 vec-
tor and the C-terminus FLAG-tag pDEST26 vector, respectively,
via the lamda-recombination reaction by use of the Gateway LR
Clonase II kit (Invitrogen). The sequences of the expression con-
structs were confirmed by sequencing. pN-FLAG ZCD2 or pC-
FLAG ZCD2 was transfected into either P19 or HEK293 cells by
use of Lipofectamine 2000 (Invitrogen) in accordance with the
manufacturer’s instructions.
Confocal Immunofluorescence Microscopy
HEK293 and P19 cells were grown on 4-well chambered slides
(Lab-Tek) overnight. The cells were transfected with either pN-
FLAG ZCD2 or pC-FLAG ZCD2 and were incubated overnight.
Cells were fixed in 4% paraformaldehyde in PBS for 20 min at
room temperature. After washing once with PBS, cells were per-
meabilized with 0.2% Triton X-100 in PBS for 10 min at room
temperature. Then, cells were blocked with 1% BSA in PBS for 30
min at room temperature. Cells were then incubated with either
anti-calnexin antibody (Santa Cruz), anti-FLAG M2 monoclonal
antibody (SIGMA), or both at a concentration of 1 mg/250 ml in
1% BSA in PBS for 1 h at room temperature. After washing twice
in 1% BSA in PBS, cells were incubated with either Alexa Fluor
488 anti-mouse (Invitrogen), Alexa Fluor 568 anti-rabbit (Invi-
trogen), or both at a dilution of 1:250 in 5% BSA in PBS for 30
min at room temperature. Cells were washed three times in PBS
and were equilibrated in the pH Equilibration solution from
SlowFade Antifade Kit with 4′,6-diamidino-2-phenylindole(DAPI)
(Invitrogen) for 10 min. DAPI mounting medium with SlowFade
was added to the cells. Confocal microscopy images were ob-
tained using a Leica TCS SP2 AOBS confocal microscope with LCS
software.
Western-Blot Analysis and Immunoprecipitation
Transfected HEK293 cells and P19 cell pellets were harvested and
then were lysed with radioimmunoprecipitation (RIPA) buffer (50
mM Tris-HCl [pH 7.4], 10 mM NaCl2, 3 mM MgCl2, 1% NP-40,
and 0.25% Na-deoxycholate) with 40 ml/ml protease inhibitor
cocktail (Sigma). The lysed cells were pelleted, and SDS loading
buffer was added in a 1:1 ratio. The lysate was denatured at 55C
for 30 min before loading onto 10% polyacrylamide gels and then
was electroblotted onto a polyvinylidene fluoride membrane
(BioRad). Primary antibodies were added at a dilution of 1:1,000
and 1:2,000 for mouse anti-FLAG (SIGMA) and rabbit anti-WFS1
(NOVUS), respectively. The appropriate secondary antibody was
then added at a dilution of 1:10,000 for the anti-mouse antibody
and 1:20,000 for the anti-rabbit antibody. Visualization of the
immunoreactive proteins was performed using Western Light-
ning chemiluminescence reagent plus (PerkinElmer).
For immunoprecipitation, 5 mg/ml of primary antibody was
added to the whole-cell lysate and was left on ice for 2 h, with
periodic agitation. Then, 50 ml of prewashed protein A sepharose
beads (Amersham) was added to the whole-cell lysate and was
incubated overnight at 4C with agitation. Beads were pelleted,
and the supernatant was discarded. The beads were then washed
with RIPA buffer twice, were resuspended in 18 ml of 2# SDS
loading buffer, and were denatured at 55C for 30 min. The pro-
teins were then analyzed by western blot.
Ca2 Studies
Lymphoblastoid cells at a concentration of cells/ml were61# 10
plated on coverslips treated with 0.1% gelatin for 48 h before
measurement of Ca2. Ca2 measurements and calculations were
performed as described elsewhere19 on single lymphoblastoid
cells. In brief, intracellular Ca2 ([Ca2]i) was measured using a
Ca2-sensitive dye, fura-2-AM (Molecular Probes). Ca2 values
were determined from the fluorescence ratio of Ca2-bound fura-
2 (excited at 340 nm) to unbound fura-2 (excited at 380 nm) in
blinded tests. For basal Ca2 measurements, 30–37 cells were mea-
sured. A subset of cells ( ) was treated with 2 mM thapsigarginnp 8
(TG). The mean SE was calculated using unpaired two-tailed t
tests with 95% CIs.
Results
Clinical Update
Family WS-2.—Individual V:2 in the original pedigree,12
who was affected, committed suicide ∼5 years before this
study, after battling with depression for a long time. In-
dividual V:9 in the original pedigree12 developed high-
frequency sensorineural hearing loss, although it is not as
severe as that in his siblings.
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Figure 1. Identification of a single base-pair change causative
of WFS2. A, Sequencing results from a control individual (left panel)
with a G at nucleotide 109 in exon 2 of the ZCD2 gene, which
codes for glutamic acid, and sequence from an affected individual
(right panel) with a homozygous C at the same position, which
changes the amino acid to glutamine. B, Truncated pedigrees of
WFS2-affected families. Genotyping of the mutation is shown be-
low the pedigrees. All pedigrees represent consanguineous mat-
ings. Only children with DNA samples are shown. Children are
numbered using designations from the original published pedi-
gree.12 The mutation disrupts an XmnI restriction-enzyme site
(GAANNNNTTC), and homozygous affected individuals show a 249-
bp fragment, whereas the wild-type allele is cut into a 210-bp
fragment and a 39-bp fragment (not shown).
Family WS-3.—Individual II:3 died ∼7 years before this
study (after the publication of the original linkage article12)
from complications of dialysis. He developed renal failure
and bleeding during dialysis. Individual II:9 died 5 years
before this study, and the cause of death is unknown.
Family WS-4.—All affected family members now have di-
abetes mellitus, optic atrophy, and high-frequency sen-
sorineural hearing loss. The diabetes mellitus is mild and
easily corrected with low doses of insulin. The hearing loss
is currently symptomatic in all four affected individuals
and not only during hearing tests.
Mutation Detection
The critical region for the WFS2 gene, between markers
D4S591 and D4S3240, is a large region representing 7.1
cM. To narrow the critical gene region, additional markers
within the region were genotyped in the families. These
include markers D4S2961, D4S3043, D4S1572, Wpoly2,
D4S2913, D4S411, and D4S1531 at the proximal end and
D4S2917, Wpoly5, Wpoly6, and Wpoly7 at the distal end.
The Wpoly markers are new microsatellite polymorphisms
identified by Sputnik, a program that scans genomic DNA,
identifies microsatellite stretches within the DNA, and
evaluates their polymorphic potential. These markers were
either uninformative in the families or did not cross the
recombination breakpoint; thus, the critical gene region
could not be reduced (data not shown).
The critical gene interval contains 62 transcripts, in-
cluding known genes, full-length cDNAs, ESTs, and pre-
dicted proteins. To reduce the gene list, predicted proteins
without a start codon and stop codon were not studied.
In addition, homology searches of the translated se-
quences by use of BLAST were also performed, which elim-
inated additional putative genes. This left 42 transcripts
in the region to be studied, including an excellent can-
didate gene, BANK1, known to induce Ca2 mobilization
in B cells.20
All the genes in the region were screened either by direct
sequencing or by SSCP analysis, starting with known genes
and full-length cDNAs. Various polymorphisms were iden-
tified, but only one nucleotide change in a novel predicted
gene, ZCD2, was found to be a WFS2 mutation in these
families. A GrC transversion in nucleotide 109 is pre-
dicted to change amino acid 37 from glutamic acid to
glutamine (E37Q) (fig. 1A). This same mutation is found
in all three families. The families are not known to be
related, but haplotype analysis had revealed a common
haplotype in the linked region,12 which would indicate a
common ancestor for this mutation. This change disrupts
an XmnI restriction-enzyme site that was used to genotype
the family members. The mutation completely segregates
with the phenotype in all three Jordanian families (fig.
1B). The mothers from all three pedigrees are shown to
be obligate carriers, and the same is assumed for the fa-
thers, although no samples were ever obtained from those
individuals. Of the 20 original samples obtained from the
children in the three families, only 16 were still currently
available to test. The original blood spots of the four in-
dividuals not tested did not yield any appreciable DNA,
and new samples were not able to be obtained.
The amplified region containing the mutation was se-
quenced in at least one affected individual in each family,
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Figure 2. Comparison of amino acid sequence of ERIS in nine species. The human sequence is shown, and identical amino acids in
other species are represented with a dash. An asterisk (*) represents a missing amino acid in that species. The bold amino acids signify
predicted conserved phosphorylation sites (b-adrenergic receptor kinase substrate at 25–29; PKA/PKC kinase substrate motif at 32–34
and 67–69; and CK2 substrate motif at 34–37). The glutamic acid that is mutated in ERIS in the Jordanian families is indicated by an
arrow. The underlined amino acids represent a putative transmembrane domain. The double-underlined amino acids highlight the zinc-
finger domain of the protein. The unblackened arrowheads indicate the region corresponding to splice junctions in the cDNA.
and all showed the 109GrC mutation. This change is not
found in the SNP database (dbSNP). Custom TaqMan SNP
genotyping for the mutation was used to screen for this
change in a large number of control individuals from var-
ious populations. Only one chromosome was identified
to have the change in the ethnically matched control pop-
ulation. One individual from the affected Jordanian fam-
ilies is part of the Jordanian control panel. Since the panel
is anonymous, it is unknown which individual from the
families is included in the control panel. The allele fre-
quency of this change is 0.08% in the Jordanian popu-
lation, and it was not found in other populations after
assessment of 2,004 chromosomes. Since this is an auto-
somal recessive condition, a very small portion of the pop-
ulation may carry this change in a heterozygous state,
although, in our panel, the single sample carrying the
change could be a carrier from the families studied.
Protein Analysis
The ZCD2 gene codes for a very small, 135-aa protein,
with a molecular weight estimated to be 15,278 Da (fig.
2). It has a predicted transmembrane domain and a single
zinc-finger domain of the CDGSH type, located close to
the carboxy terminus. This zinc finger is similar to do-
mains in the protein encoded by another human gene
(ZCD1) and to those in proteins in many single-cell or-
ganisms, all of unknown function. Protein homologues
from dog, mouse, rat, chicken, two frog species, two fish
species, and Drosophila melanogaster have been identified.
The protein is highly conserved and has 70% identity and
82% similarity across all the vertebrate species (fig. 2). The
human and Drosophila proteins are 46% identical and 68%
similar. Several serine and/or threonine and one tyrosine
phosphorylation sites were identified in the human pro-
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tein, although only four serine and/or threonine sites are
conserved in all species, including Drosophila (fig. 2). The
protein has a single b-adrenergic receptor kinase site at
amino acids 25–29 ([E/D][S/T]XXX),21 two PKA/PKC ki-
nase motifs at amino acids 32–34 and 67–69 ([R/K]X[S/
T]),22 and a single CK2 (formerly, casein kinase 2) phos-
phorylation site ([S/T]XX[D/E])23 at amino acids 34–37,
which encompasses the mutation in the last position.
Hearing-Loss Mutation Screen
Although WFS is a recessive disorder, dominant mutations
in the WFS1 gene have been associated with nonsyn-
dromic hearing loss and optic atrophy with hearing im-
pairment.9–11 Six families with WFS1 mutations have low-
frequency sensorineural hearing loss,9 and one additional
family has progressive hearing loss, with mild hearing loss
in the low-frequency range but advanced-to-moderate
hearing loss across all frequencies.10 Hearing loss in WFS
mostly involves high frequencies, which is also observed
in WFS2-affected families.3,12 To determine whether ZCD2
is involved in deafness in a general hearing-loss–affected
population, we screened 377 probands for mutations in
ZCD2. No mutations were identified in this cohort, so it
seems that ZCD2 is not commonly involved in nonsyn-
dromic deafness. Only one proband had low-frequency
sensorineural hearing loss, so it remains to be determined
whether ZCD2 is involved in this subset of hearing loss.
Expression Studies
By use of RT-PCR on RNA from a variety of human tissues,
expression was observed in the majority of tissues, in-
cluding brain and pancreas. Expression was not observed
in cartilage, fetal liver, and skeletal muscle (fig. 3A).
Disease Pathogenesis
The mutated glutamic acid is conserved in all species ex-
cept mouse, in which there is an aspartic acid residue in
its place (fig. 2). The replacement of the glutamic acid
residue at position 37 with aspartic acid does not disrupt
the CK2 phosphorylation site. This site is also found in
Drosophila, although the sequence is divergent (SFKD).
The mutation changes the conserved glutamic acid from
the single conserved CK2 site, which would abolish phos-
phorylation at this site. It would be logical to conclude
that the disruption of a functional domain would be in-
dicative of disease pathogenesis, but, in actuality, the mu-
tation also creates a splice-site mutation.
The mature cDNA is derived from three exons. The mu-
tated base is located close to the 5′ end of exon 2, 6 bases
from the intron-exon junction. Performance of RT-PCR
with primers that amplify the full-length cDNA on tem-
plates derived from lymphoblastoid RNA from an affected
individual and two controls showed a 336-bp product in
the affected individual and a 551-bp product of expected
size in controls (fig. 3B). Sequencing the RT-PCR products
showed that the 336-bp product is the result of exon 2
being skipped in the final transcript (fig. 3C). This smaller
RT-PCR product is not observed in RNA from other tissue
types and is likely not a splice variant (data not shown).
The aberrant splice product would code for the 34 aa
from exon 1, but the frameshifts in exon 3 would create
a premature stop codon after 8 additional aa. This would
eliminate 75% of the protein, including the transmem-
brane and zinc-finger domains. This particular nucleotide
change does not reside in any known splice-acceptor or
-donor regions; thus, it is likely that this change disrupts
an exonic splice enhancer (ESE).
ERIS Cellular Localization
To determine the cellular localization of ZCD2, the human
gene was tagged with FLAG on the amino (N-) or carboxy
(C-) terminus and was expressed in mouse P19 and human
HEK293 cells. N-FLAG protein is localized to the ER, co-
localizing with calnexin, a known ER marker24 (fig. 4A).
Because of the protein’s predicted domains and cellular
localization, we have named the ZCD2-encoded protein
“ERIS” (endoplasmic reticulum intermembrane small
protein).
No Interaction of ERIS with Wolframin
To determine whether ERIS interacts directly with the
WFS1-encoded protein, Wolframin, coimmunoprecipita-
tion studies were performed in cell lines expressing N-
FLAG and C-FLAG ERIS. Wolframin did not coprecipitate
with ERIS (fig. 4B).
Ca2 Measurements
Resting [Ca2]i levels were not significantly different in a
lymphoblastoid cell line derived from an affected individ-
ual compared with those in a cell line from an unaffected
control (fig. 5A). When stimulated by TG, a known stim-
ulator of ER Ca2 release, there was significantly more in-
tracellular Ca2 release in the affected cell line than in the
unaffected cell line (fig. 4B–4D).
Discussion
The majority of WFS cases seem to be caused by mutations
in the WFS1 gene, but, in many studies, there has been
evidence of genetic heterogeneity.12,25–27 We have shown
that a mutation in a zinc-finger gene, ZCD2, also causes
WFS. The same missense mutation was identified in all
three unrelated, consanguineous Jordanian families stud-
ied. Through haplotype analysis, it is clear that these fam-
ilies share a common ancestor.12 Although the missense
mutation occurs at a conserved amino acid, the actual
pathogenesis of the nucleotide change has been shown to
affect mRNA splicing. The mutation causes exon 2 to be
skipped, which results in a frameshift leading to a pre-
mature stop codon, resulting in 175% of the protein to
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Figure 3. ZCD2 expression and WFS2 disease pathogenesis. A, RT-PCR of the WFS2 gene, ZCD2, in a variety of tissues (top row) and
the GADPH control (bottom row). B, RT-PCR of lymphoblastoid RNA from two control individuals (C1 and C2) and an affected individual
(A), by use of human ZCD2 cDNA primers. The primers amplify the full-length cDNA; the large band is 551 bp, and the smaller band is
336 bp. Lane M is the molecular marker. C, Genomic sequence of the intron-exon boundary shows that the mutation (bold and underlined)
is within 6 bp of the 3′ splice-acceptor site. Below, cDNA and amino acid sequences are shown at the boundary between exon 1 and
exon 2, compared with the premature stop codon that occurs when exon 1 and exon 3 are spliced together in an affected individual.
be missing, including a putative transmembrane domain
and the zinc-finger domain. Although the mutation func-
tionally affects splicing, the 10 bp surrounding the mu-
tation site does not demonstrate any consensus for ESEs.
Some of the best-defined ESEs share one of two features.
One class of ESEs shows high purine content (80%), al-
though specific sequences within that region are known
to be important; the second class of ESEs is A/C rich.28
ZCD2 encodes 60% purines in the sequence adjacent to
the mutation, and the region is not particularly AC rich.
In fact, the mutation replaces a G with a C. It is well known
that a large number of sequences can function as ESEs but
do not conform to any specific sequence. We have iden-
tified a functional ESE in ZCD2 that does not conform to
a known class of ESEs.
We did not identify mutations in ZCD2 in a large cohort
of 377 individuals from multiplex families with nonsyn-
dromic deafness. Dominant mutations in the WFS1 gene
have been reported in DFNA6/14-affected families with
low-frequency sensorineural hearing loss or progressive
hearing loss.9,10 Of the 377 probands, 240 had autosomal
recessive inheritance, 84 had dominant hearing loss, and
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Figure 4. Localization and immunoprecipitation of ERIS. A, P19
cells transfected with pN-FLAG ZCD2. In panel 1, the transfected
cells were stained with DAPI. Panel 2 shows the ER marker calnexin
(red). Panel 3 shows pN-FLAG ZCD2 (green). Only a proportion of
the cells that were transfected showed pN-FLAG ZCD2 expression.
Panel 4 shows the merged picture, with pN-FLAG ZCD2 colocalizing
with calnexin in the ER. B, Cell lysates from HEK293 cells trans-
fected with pC-FLAG ZCD2, immunoprecipitated using anti-WFS1
antibodies (lane 1) and anti-FLAG antibodies (lane 2). The top
half of the blot was probed with anti-WFS1 antibodies, and the
bottom half with anti-FLAG antibodies. Lane 1 shows a strong
Wolframin band at 100 kDa but does not show pC-FLAG ZCD2 (at
17.5 kDa). pC-FLAG ZCD2 is observed in lane 2, with no Wolframin.
The 19-kDa band represents immunoglobulin G, whereas other
bands represent nonspecific binding of the antibodies. The same
results were observed when the experiment was performed with
pN-FLAG ZCD2 (data not shown).
53 were heterozygous for a single change in the GJB2 gene.
Although the majority had severe-to-profound hearing
loss, 14 had high-frequency hearing loss but only 1 had
low-frequency hearing loss. ZCD2 does not seem to be
generally associated with nonsyndromic hearing loss, but
it remains to be determined whether it is specifically as-
sociated with low-frequency hearing loss, similar to the
WFS1 gene.
ZCD2 has a fairly wide expression profile, including the
pancreas and brain, two tissues affected by the disorder.
Since the transcript could be amplified from RNA derived
from lymphoblastoid cells, it may also be expressed in
blood cell lineages. Expression studies using mass spec-
trometry listed in the Human Protein Reference Database
(accession number 17413) show the presence of ZCD2
transcripts in platelets.17 This would correlate with the
bleeding phenotype described in these families.
Although we did not perform in situ hybridization on
tissue sections, these experiments were performed on sag-
ittal sections with the mouse Zcd2 transcript (accession
number 1500009M05Rik) as part of the Allen Brain Atlas
project.29 Expression of the gene in adult mouse brain is
observed in a wide variety of structures, including the ce-
rebral cortex, piriform area, pyramidal cells of the hip-
pocampus, the central amygdalar nucleus, the medulla,
pons, thalamus, inferior and superior colliculus of the
brainstem, and the Purkinje cell layer and dentate nucleus
of the cerebellum. Interestingly, there is substantial over-
lap of expression of Zcd2 in mice and Wfs1 in rat brain.7
These brain regions primarily control memory, emotions,
and motor skills. Affected individuals with WFS are known
to have neurological complications, such as cerebellar
ataxia and myoclonus, as well as psychiatric illness.4
Magnetic resonance imaging studies of individuals with
WFS show degeneration of the brainstem, cerebellum, op-
tic nerve, tracts, and chiasm.30 A small number of WFS-
affected brains have been studied postmortem. These stud-
ies show the degeneration of specific brainstem structures
and also show a much wider pathology.31,32 Neural degen-
eration of many other areas where Zcd2 is expressed is also
observed. These include the superior and inferior colliculi
and the thalamus (brainstem), as well as the pontine nu-
clei, Purkinje cells, and pons. Loss of the cochlear nerves
and mild loss of cochlear nuclei has also been observed.
In general, it appears that neurodegeneration in WFS is
correlated with the spatial expression of ZCD2. Because
the loss of sensory neurons, pancreatic b cells, or absence
or hypoplasia of the hypothalamus could explain the
main clinical symptoms, ZCD2 expression in these tissues
needs to be examined further.
ERIS is an extremely small but well-conserved protein.
Indirect immunofluorescence studies show that the pro-
tein is localized to the ER. ERIS does not have a predicted
ER signal sequence at the amino terminus but has a single
transmembrane domain. Transmembrane proteins have
been shown to use their first transmembrane domain to
be directed into the ER.33 The other major predicted do-
main is a zinc-finger domain of the CDGSH type with a
CCHH finger. Zinc-finger domains are now known to be
able to bind nucleic acids, lipids, and proteins.34 Wolfra-
min coimmunoprecipitation studies performed in cell
lines expressing N- or C-FLAG ERIS revealed that Wolfra-
min does not coprecipitate or interact with ERIS.
Wolframin has been well studied and has been shown
to localize to the ER and play a role in modulating [Ca2]i.
www.ajhg.org The American Journal of Human Genetics Volume 81 October 2007 681
Figure 5. Intracellular Ca2 measurements. A, No difference in the mean basal [Ca2]i levels observed between wild-type and mutant
cells ( ; ). B, The mean [Ca2]i increase, significantly greater in mutant cells than in wild-type cells when stimulatednp 30–37 Pp .49
with 2 mM TG ( ; the asterisk [*] indicates significance [ ]). Also shown are representative single-cell measurements ofnp 8 Pp .03
[Ca2]i changes in mutant (C) and wild-type (D) cells when stimulated by TG.
Although [Ca2]i levels between WFS2-affected and con-
trol lymphoblastoid cells were not significantly different,
a significantly greater increase in [Ca2]i in affected cells
was observed when they were stimulated with TG. TG is
a known inhibitor of the sarco(endo)plasmic reticulum
Ca2ATPase, which results in ER Ca2 efflux.35 This is con-
sistent with a role for ERIS in [Ca2]i homeostasis in cells
expressing the gene. Recently, it has been shown that
knockdown of WFS1 in HEK293 cells showed lower in-
creases in Ca2 when TG was added to the media, sug-
gesting lower levels of Ca2 in the ER ([Ca2]ER) in cells
without Wolframin.36 Measuring the rate at which Ca2
moves back into the ER showed that this rate was de-
creased, indicating a role for Wolframin in ER Ca2 up-
take.36 Additional studies need to be undertaken to de-
termine whether greater TG-stimulated Ca2 release in
WFS2-affected cells is because of higher [Ca2]ER.
The symptoms of this disorder are caused by degener-
ation of neurons and pancreatic b cells. [Ca2]ER is impor-
tant not only for signaling but also for the folding and
processing of newly synthesized proteins, which have
shown to be Ca2-dependent reactions.37,38 Cell lines and
animals with WFS1 insufficiency have shown ER stress,
which triggers the unfolded protein response (UPR), im-
pairs cell-cycle progression, and increases apoptosis in
pancreatic b cells.39,40 Wolcott-Rallison syndrome (MIM
226980), a rare autosomal recessive disorder that has in-
fancy-onset diabetes as one of its symptoms, is caused by
mutations in EIF2AK3, encoding translation initiation fac-
tor 2-alpha kinase 3, a kinase important in the UPR.41 Fold-
ing and processing of newly synthesized proteins require
high Ca2 levels; thus, higher-than-normal [Ca2]ER may
not impair protein folding and trigger the UPR.
High [Ca2]ER has been shown to have a number of dif-
ferent cellular effects. It can increase the Ca2 release rate
constant in cardiomyocytes42,43; can affect the sensitivity
of the ryanodine receptor, a major ER Ca2 release chan-
nel44,45; and can inhibit Ca2 uptake and affect the velocity
of uptake in mouse pancreatic acinar cells and sensory
neurons from dorsal root ganglia of rats.46,47 Interestingly,
knock-in of presenilin-1 Alzheimer mutations in mice
shows increased [Ca2]ER.
48 In hippocampal neurons from
these mice, glutamate-induced oxidative stress and mi-
tochondrial dysfunction is enhanced, resulting in a lower
threshold for excitotoxic neuronal necrotic cell death.49
The mitochondria are also an important component in
Ca2 signaling, since they can rapidly sequester Ca2 after
an initial Ca2 pulse and slowly release it during the re-
covery phase, through a permeability transition pore
(PTP).50,51 Overloading the ER with Ca2 enhances the sen-
sitivity of ceramide-induced apoptosis, through the over-
load of Ca2 in the mitochondria, and the release of
cytochrome c, through the formation of the PTP.52,53
Disturbing Ca2 homeostasis seems to predispose cells to
multiple forms of cell death.
WFS has now been shown to be caused by at least two
different genes, WFS1 and ZCD2. They both encode ER
proteins and seem to affect cellular Ca2 homeostasis.
WFS1 has also been implicated in nonsyndromic hearing
loss and optic atrophy. ZCD2 could be important in iso-
lated cases of these disorders. It remains to be determined
whether the two genes reside in the same pathway and
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what specific mechanism each gene uses that leads to
nerve and pancreatic degeneration.
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